Systematic (IUPAC) name | |
---|---|
(6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}- 3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a601206 |
Pregnancy cat. | B1(AU) |
Legal status | POM (UK) Discontinued (US) |
Routes | Intramuscular, intravenous |
Pharmacokinetic data | |
Protein binding | 75% |
Half-life | 48 minutes |
Excretion | Mostly renal, as unchanged drug |
Identifiers | |
CAS number | 34444-01-4 42540-40-9 |
ATC code | J01DC03 |
PubChem | CID 456255 |
DrugBank | DB01326 |
ChemSpider | 401748 |
UNII | 5CKP8C2LLI |
KEGG | D02344 |
ChEBI | CHEBI:3480 |
ChEMBL | CHEMBL1146 |
Chemical data | |
Formula | C18H18N6O5S2 |
Mol. mass | 462.505 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Cefamandole (INN, also known as cephamandole) is a second-generation broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally.
Cefamandole is no longer available in the United States.
The chemical structure of cefamandole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase)(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.[1]